BNET Industries

Pfizer Inc.

(PFE) is in the Pharma Industry

Market Cap:$150.4B

Last Fiscal Year Sales:$48.4B

Public
US

Dow Jones Description

Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.

Number of Employees 81,800

Contact Information

235 E 42nd St

New York, New York 10017-5755

www.pfizer.com

(212) 573-2323

Peer Companies

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Company News

Recent Events

Pfizer and B.C. launch $9M collaboration to tackle cancer

12/03/09 - Joint Venture / Alliance - View Story
Reportlinker Adds Growth Factors Blood And Tissue - A World Report

12/02/09 - Joint Venture / Alliance - View Story
Barclays appoints US lev loan syndicate head - memo

12/02/09 - Merger / Acquisition - View Story
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa

12/02/09 - Joint Venture / Alliance - View Story
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M

12/02/09 - Joint Venture / Alliance - View Story
Roche's Merger Formula for Genentech

11/30/09 - Merger / Acquisition - View Story
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV

11/24/09 - Joint Venture / Alliance - View Story
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...

11/27/09 - Financial Announcement - View Story
A 2nd Loss for Pfizer in Drug Suits

11/23/09 - Legal Settlement - View Story
Pfizer acquires stem cell therapies assets of Axordia

11/23/09 - Merger / Acquisition - View Story
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24

11/23/09 - Bond / Stock Rating - View Story
ImmunoVaccine signs exclusive licence deal with Pfizer

11/23/09 - Joint Venture / Alliance - View Story
Pfizer Animal Health selects Bader Rutter as agency of record

11/17/09 - Licensing / Contract - View Story
FDA panel backs Pfizer's anti-infection vaccine for kids

11/19/09 - Merger / Acquisition - View Story
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started

11/16/09 - Joint Venture / Alliance - View Story
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China

11/16/09 - Bond / Stock Rating - View Story
EDITORIAL: Difficult mix of business, science

11/24/09 - Merger / Acquisition - View Story
$75M verdict unsealed in Prempro-cancer case

11/27/09 - Merger / Acquisition - View Story
Sanofi-Aventis on hunt for Boston partners

11/11/09 - Merger / Acquisition - View Story

News & Analysis

Filter by

Sort Type

agreement and pfizer inc. and pharmaceutical company - All News and Analysis

Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE Tablets in Mexico; Pfizer, S.A. De C.V. to Advance Commercialization of the Fluoroquinolone Antibiotic in Mexico

- 2006-02-07

WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has sublicensed the commercialization rights to FACTIVER gemifloxacin mesylate tablets in Mexico to Pfizer, S.A. de C.V. Pfizer Mexico, the largest pharmaceutical company in that country. In exchange for those rights, Pfizer Mexico has agreed to pay Oscient an up-front payment, milestones...

Tags: agreement, Pfizer Inc., pharmaceutical company, tablet
PFIZER INC - Re Agreement.

- 2005-03-24

Pfizer, Coley Pharmaceutical Group Enter Into Exclusive Global License For The Development and Commercialization of ProMuneTM for Cancers NEW YORK and WELLESLEY, Mass., March 24 -- Pfizer Inc and Coley Pharmaceutical Group,...

Tags: agreement, Pfizer Inc., pharmaceutical company
Teva Announces Agreement to Acquire Pfizer's Italian Generic Pharmaceutical Operation

- 2004-08-17

JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that it has reached an agreement to acquire Pfizer's Italian generic pharmaceutical marketing company, Dorom S.r.l. The cash transaction, which is valued at up to 2.3 times sales, subject to adjustments, is expected to close in December 2004, subject to closing...

Tags: agreement, Pfizer Inc., pharmaceutical company